It’s been a choppy day for London’s AIM Index, with early gains being reversed before the junior market pushed higher to the close, finishing up almost nine points at 1024.22
- N4 Pharma +33%
- UkrProduct +27%
- PurpleBricks +21%
- Synairgen -15%
- MyHealthChecked -12%
N4 Pharma LON:N4P topped the board today, adding 33% by the close. The share price has been under pressure since the end of last year and there’s no news out to support the gains, but volumes have certainly been exaggerated. There’s quite a chunky spread on this but the market cap of £5m goes some way to explaining that. Even so, it seems as if sellers may be thin on the ground.
UkrProduct LON:UKR is back in focus, adding another 27% by the bell on Thursday. This is by all accounts a great Ukrainian rebound play and assuming we hopefully see a prompt resolution here, demand from overseas investors into the country is likely to be brisk. Could this by default end up being a suitable vehicle here?
A notable mention for PurpleBricks LON:PURP which tacked on an impressive 21% today. The only news here was a PDMR notification of someone buying up shares in the company, but volumes were comparatively light. Perhaps the most notable point is that the gains have come off the back of the Bank of England rate hike which ought to have some potential to cool the housing market.
Synairgen LON:SNG was the day’s worst performer, sliding 15% by the bell. The company provided a trial update this morning, with its US partner announcing it had halted all patient recruitment. The therapy was designed to tackle COVID but the significant evolution of the disease means that the current approach is no longer valid. However there’s still plenty to like here in terms of the success and adaptability to other respiratory conditions.
MyHealthChecked LON:MHC was also a notable laggard on the day, sliding some 12% by the bell. Again there’s no news but thin trade drove the spread out to 15%, making this a difficult call. With COVID testing rapidly diminishing, the company arguably needs to accelerate progress on its other self-diagnostic kits. Consumers are used to the concept off the back of the pandemic, so there could still be great potential here.
